Proactive Investors - Run By Investors For Investors

Pharmaxis expects an FDA decision on Bronchitol mid-year after positive committee recommendation

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the positive recommendation received from a US Food and Drug Administration advisory committee for the use of its inhaled powder Bronchitol in adult patients with cystic fibrosis. 
Phillips says the US is the last major territory where Bronchitol has not yet been approved and the company expects an FDA decision mid-year.
Clinical trials have shown Bronchitol improves lung function in CF patients.
It is delivered by a portable inhaler, allowing patients to fit in taking medication with their daily lives.


Meet West Wits Mining Limited, Global Energy Ventures Ltd, XTEK Ltd and ShareRoot Ltd at our event, Melbourne , 04 June 2019. Register here »
View full PXS profile View Profile

Pharmaxis Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use